Clinical Trial Phases

Phase 2 clinical trials serve as a critical checkpoint in the drug development process. After a drug demonstrates basic safety in Phase 1, it enters Phase 2 to begin evaluating whether it works in a specific patient population. The three core objectives of Phase 2 studies are to assess safety, measure efficacy, and identify or refine the optimal dose for further development. This tutorial explores each of these objectives in detail, outlining their roles in advancing promising therapies through the clinical pipeline.
Click to read the full article.

Phase 2 clinical trials serve a dual purpose—exploring efficacy and optimizing dose—before a treatment enters large-scale confirmatory trials. To better structure these goals, Phase 2 is often divided into two subphases: Phase 2A and Phase 2B. Understanding the distinction between these trial types helps researchers design better studies, streamline development, and make clearer go/no-go decisions. This tutorial explores the purpose, design, and application of Phase 2A vs. Phase 2B trials in clinical development.
Click to read the full article.

The transition from Phase 1 to Phase 2 is one of the most critical decision points in drug development. It marks the move from initial human safety testing to early efficacy evaluation in patients. This step involves careful analysis of safety data, pharmacokinetics, dosing feasibility, and early biological activity. In this tutorial, we explore the criteria used to determine whether an investigational product is ready for Phase 2, the common pitfalls that delay progression, and the strategic planning needed to make the transition successful.
Click to read the full article.